Investigational drug · Phase 2
iscalimab
Also called: CFZ533
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hidradenitis Suppurativa.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
11
Any phase or sponsor naming "iscalimab"
First trial start
2019
Feb 27, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "iscalimab", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa
Approved drugs for the same conditions: Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "iscalimab" as an intervention, largest first.
- Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's SyndromePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03905525 · 273 participants · Start Oct 1, 2019 · Primary completion Sep 28, 2022
Drug: CFZ533 · For: Sjögren Syndrome
Sites: Suwanee, Georgia; Indianapolis, Indiana; Baton Rouge, Louisiana · 71 sites in all
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03827798 · 248 participants · Start Feb 27, 2019 · Primary completion Dec 4, 2024
Drug: CFZ533; Placebo to CFZ533 and 9 more · For: Hidradenitis Suppurativa
Sites: Clearwater, Florida; Orange Park, Florida; Tampa, Florida · 36 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04541589 · 206 participants · Start Jan 5, 2021 · Primary completion Aug 19, 2024
Drug: Iscalimab · For: Sjogren's Syndrome
Sites: Suwanee, Georgia; Baton Rouge, Louisiana; Baltimore, Maryland · 62 sites in all
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term ExtensionPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT03781414 · 129 participants · Start Oct 7, 2019 · Primary completion Apr 20, 2023
Drug: CFZ533; Tacrolimus - MMF - corticosteroids · For: Liver Transplant Rejection
Sites: Los Angeles, California; Aurora, Colorado; Chicago, Illinois · 29 sites in all
- Study the Efficacy and Safety of VAY736 and CFZ533 in SLE PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03656562 · 107 participants · Start Dec 19, 2018 · Primary completion Jul 27, 2022
Drug: VAY736; VAY736 Placebo and 2 more · For: Systemic Lupus Erythematosus (SLE)
Sites: Caba, Argentina; Clayton, Australia; Guangzhou, China · 31 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02089087 · 75 participants · Start Jan 7, 2013 · Primary completion Feb 3, 2017
Drug: CFZ533; Placebo · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Miami, Florida; South Miami, Florida · 6 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02217410 · 59 participants · Start Feb 5, 2015 · Primary completion Nov 29, 2017
Drug: CFZ533; Tacrolimus (Tac) and 3 more · For: Kidney Transplantation
Sites: Aurora, Colorado; Baltimore, Maryland; Ann Arbor, Michigan · 14 sites in all
- Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.Completed
Novartis PharmaceuticalsNovartis (NVS)
NCT03610516 · 57 participants · Start Sep 12, 2018 · Primary completion Jun 29, 2023
Drug: CFZ533; Placebo · For: Lupus Nephritis
Sites: Ciudad Autonoma de Bs As, Argentina; Córdoba, Argentina; Guangzhou, China · 21 sites in all
- Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult SubjectsCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04129528 · 44 participants · Start Nov 8, 2019 · Primary completion Jan 15, 2024
Drug: CFZ533 · For: Type 1 Diabetes Mellitus
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 12 sites in all
- Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia GravisCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02565576 · 44 participants · Start Sep 29, 2015 · Primary completion Jul 31, 2017
Drug: Placebo; CFZ533 · For: Myasthenia Gravis, Generalized
Sites: Montreal, Canada; Québec, Canada; Aarhus, Denmark · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging Therapeutic Strategies for Graves' Disease: Current Advances and Future Perspectives.
Antonelli A, Fallahi P · Curr Pharm Des 2026
- Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives.
Yazisiz V · Expert Opin Pharmacother 2026
- Efficacy and safety of pharmacological treatment for Sjögren's disease: a network meta-analysis.
Yang M, Lu Y, Wang S, et al. · Z Rheumatol 2026
- Advances and unmet needs in the management of proliferative lupus nephritis: evidence, guidelines, and emerging therapies.
Lee S · Kidney Res Clin Pract 2026
- [Pathophysiological aspects of primary Sjögren's disease : From epithelial activation to systemic autoimmunity].
Ritter J, Dörner T · Z Rheumatol 2026
- How to manage autoimmune hyperthyroidism (Graves' disease): from differential diagnosis to emerging immunological therapies.
Karapanou O, Saltiki K, Markantes GK, et al. · Drugs Context 2026
Also in development for Hidradenitis Suppurativa
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- SonelokimabPhase 37 trials
MoonLake Immunotherapeutics AG · Hidradenitis Suppurativa, Arthritis, Psoriatic
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MAS825ArumakimigPhase 24 trials
Novartis · NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome
- EltrekibartLY3041658Phase 22 trials
Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.